Gessner, Arne http://orcid.org/0000-0002-1729-4231
Gemeinhardt, Anna
Bosch, Agnes
Kannenkeril, Dennis
Staerk, Christian
Mayr, Andreas
Fromm, Martin F.
Schmieder, Roland E.
Maas, Renke
Funding for this research was provided by:
Friedrich-Alexander-Universität Erlangen-Nürnberg
Article History
Received: 17 September 2021
Accepted: 25 December 2021
First Online: 6 January 2022
Change Date: 27 January 2022
Change Type: Update
Change Details: The errors in the tables and supplementary material have been corrected.
Declarations
:
: Written informed consent was obtained from each patient before study inclusion. The study protocol of each trial was approved by the German drug authority and Local Ethics Committee (University of Erlangen-Nürnberg), and the studies were conducted in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice guidelines.
: Not applicable.
: A. Gessner was involved in research projects at his institution by Boehringer Ingelheim. M.F. Fromm has received consultancy fees from Boehringer Ingelheim and lecture fees from Janssen-Cilag. He has received third-party funds for research projects at his institution by Boehringer Ingelheim, Dr. R. Pfleger GmbH, and Heidelberg Pharma Research GmbH.R.E. Schmieder has received speaker fees and advisory board fees from Boehringer Ingelheim and AstraZeneca. The other authors declare that they have no competing interests.